We are live on ! Find out more
ADIL icon

Adial Pharmaceuticals
ADIL

11 hedge funds and large institutions have $1.17M invested in Adial Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,120% more capital inflows, than outflows

Capital inflows: $277K | Capital outflows: $22.7K

0% more funds holding

Funds holding: 11 → 11 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.11% less ownership

Funds ownership: 6.39% → 6.28% (-0.11%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$217K
2
Renaissance Technologies
Renaissance Technologies
New York
+$60.5K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$18K
2
Osaic Holdings
Osaic Holdings
Arizona
-$2.71K
3
Victory Capital Management
Victory Capital Management
Texas
-$2K

ADIL Hedge Fund Activity: Q2 2020 in Review

11 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2020, worth a combined $1.17M — up 35% from $869K a quarter earlier.

Fund positioning in ADIL was balanced in Q2 2020: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Bank of America, opening a new position worth an estimated $217K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $18K sold.

  • 11 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2020, unchanged from Q1 2020.
  • Funds reported $1.17M of Adial Pharmaceuticals stock for Q2 2020, up 35% quarter-over-quarter.
  • 2 funds opened new Adial Pharmaceuticals positions in Q2 2020 and 2 closed out, a net change of 0 holders.
  • The largest Adial Pharmaceuticals buyer in Q2 2020 was Bank of America, an estimated $217K added.
  • The largest Adial Pharmaceuticals seller in Q2 2020 was Susquehanna International Group, an estimated $18K sold.

Based on aggregated 13F filings for Q2 2020.